208 related articles for article (PubMed ID: 20675396)
21. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors.
Van Hout MC; Bingham T
Int J Drug Policy; 2012 May; 23(3):188-97. PubMed ID: 22342322
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
23. Mephedrone related fatalities: a review.
Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3777-90. PubMed ID: 26502870
[TBL] [Abstract][Full Text] [Related]
24. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model.
Wood DM; Greene SL; Dargan PI
Emerg Med J; 2013 Jan; 30(1):70-1. PubMed ID: 22034538
[TBL] [Abstract][Full Text] [Related]
25. How the media helped ban mephedrone.
Sare J
BMJ; 2011 Feb; 342():d1138. PubMed ID: 21349891
[No Abstract] [Full Text] [Related]
26. [Mephedrone, the new designer drug of abuse: pharmacokinetics, pharmacodynamics and clinical and forensic issues].
Ribeiro E; Magalhães T; Dinis-Oliveira RJ
Acta Med Port; 2012; 25(2):111-7. PubMed ID: 22985922
[TBL] [Abstract][Full Text] [Related]
27. Patterns of presentation and clinical features of toxicity after reported use of ([2-aminopropyl]-2,3-dihydrobenzofurans), the 'benzofuran' compounds. A report from the United Kingdom National Poisons Information Service.
Kamour A; James D; Lupton DJ; Cooper G; Eddleston M; Vale A; Thompson JP; Thanacoody R; Hill SL; Thomas SH
Clin Toxicol (Phila); 2014 Dec; 52(10):1025-31. PubMed ID: 25345418
[TBL] [Abstract][Full Text] [Related]
28. Mephedrone and other cathinones.
Zawilska JB
Curr Opin Psychiatry; 2014 Jul; 27(4):256-62. PubMed ID: 24852055
[TBL] [Abstract][Full Text] [Related]
29. Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity.
Wood DM; Dargan PI
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):227-33. PubMed ID: 22564711
[TBL] [Abstract][Full Text] [Related]
30. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.
Schifano F; Albanese A; Fergus S; Stair JL; Deluca P; Corazza O; Davey Z; Corkery J; Siemann H; Scherbaum N; Farre' M; Torrens M; Demetrovics Z; Ghodse AH; ;
Psychopharmacology (Berl); 2011 Apr; 214(3):593-602. PubMed ID: 21072502
[TBL] [Abstract][Full Text] [Related]
31. Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing.
Herzig DA; Brooks R; Mohr C
Hum Psychopharmacol; 2013 Mar; 28(2):168-82. PubMed ID: 23532749
[TBL] [Abstract][Full Text] [Related]
32. Deaths of individuals aged 16-24 years in the UK after using mephedrone.
Loi B; Corkery JM; Claridge H; Goodair C; Chiappini S; Gimeno Clemente C; Schifano F
Hum Psychopharmacol; 2015 Jul; 30(4):225-32. PubMed ID: 26216555
[TBL] [Abstract][Full Text] [Related]
33. Case series of individuals with analytically confirmed acute mephedrone toxicity.
Wood DM; Davies S; Greene SL; Button J; Holt DW; Ramsey J; Dargan PI
Clin Toxicol (Phila); 2010 Nov; 48(9):924-7. PubMed ID: 21171849
[TBL] [Abstract][Full Text] [Related]
34. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.
Uosukainen H; Tacke U; Winstock AR
Int J Drug Policy; 2015 Jan; 26(1):78-83. PubMed ID: 25107829
[TBL] [Abstract][Full Text] [Related]
35. 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.
Gallagher CT; Assi S; Stair JL; Fergus S; Corazza O; Corkery JM; Schifano F
Hum Psychopharmacol; 2012 Mar; 27(2):106-12. PubMed ID: 22389075
[TBL] [Abstract][Full Text] [Related]
36. Buying 'legal' recreational drugs does not mean that you are not breaking the law.
Ramsey J; Dargan PI; Smyllie M; Davies S; Button J; Holt DW; Wood DM
QJM; 2010 Oct; 103(10):777-83. PubMed ID: 20675395
[TBL] [Abstract][Full Text] [Related]
37. Limited use of novel psychoactive substances in South London nightclubs.
Wood DM; Hunter L; Measham F; Dargan PI
QJM; 2012 Oct; 105(10):959-64. PubMed ID: 22718853
[TBL] [Abstract][Full Text] [Related]
38. Instability of the ecstasy market and a new kid on the block: mephedrone.
Brunt TM; Poortman A; Niesink RJ; van den Brink W
J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
[TBL] [Abstract][Full Text] [Related]
39. [Mephedrone: a new synthetic drug].
Petit A; Karila L; Sananes M; Lejoyeux M
Presse Med; 2013 Oct; 42(10):1310-6. PubMed ID: 23669315
[TBL] [Abstract][Full Text] [Related]
40. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective.
Cosbey SH; Peters KL; Quinn A; Bentley A
J Anal Toxicol; 2013 Mar; 37(2):74-82. PubMed ID: 23354334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
